Analyst Price Targets — IONS
Latest News for IONS
Ionis Pharmaceuticals (NASDAQ: IONS - Get Free Report) and Purple Biotech (NASDAQ: PPBT - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations. Earnings and Valuation This table compares Ionis Pharmaceuticals
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
ADAR1 Capital Management LLC acquired a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 166,286 shares of the company's stock, valued at approximately $13,185,000. ADAR1 Capital Management LLC owned
Biotech has been hot in 2026. The sector, tracked by the SPDR S&P Biotech ETF, (XBI +1.44%) is up 39% year to date -- beating tech and running even with energy.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that new data in the management of severe hypertriglyceridemia (sHTG) will be presented at the European Society of Cardiology (ESC) Congress 2026, taking place August 28 – 31 in Munich. Presentations include one-year data from the open-label, long-term extension study of TRYNGOLZA® (olezarsen), recently approved in the U.S.…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.